Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

MNTA
Momenta Pharmaceuticals, Inc. Common Stock
stock NASDAQ

Inactive
Sep 30, 2020
52.48USD-0.019%(-0.01)8,010,618
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Oct 1, 2020
08:45AM EDT  Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, Momenta or the Company), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the successful completion of its sale to Johnson & Johnson for $52.50 per share, totaling approximately $6.5 billion.   GlobeNewswire Inc
Sep 25, 2020
05:48PM EDT  Chesapeake Utilities to Join S&P SmallCap 600   PR Newswire
Sep 17, 2020
04:31PM EDT  ALERT: Halper Sadeh LLP Is Investigating the Following Mergers; Shareholders   PR Newswire
Sep 16, 2020
02:32PM EDT  Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Rosetta Stone Inc. (NYSE: RST), Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Jernigan Capital, Inc. (NYSE: JCAP), and Varian Medical Systems, Inc. (NYSE: VAR). Additional information about each potential action can be found at the link provided.   GlobeNewswire Inc
Sep 15, 2020
08:19AM EDT  Momenta Pharmaceuticals Announces Expiration Of Hart-Scot-Rodino Waiting Period In Connection With Proposed Sale To Johnson & Johnson   Benzinga
08:00AM EDT  Momenta Pharmaceuticals Announces Expiration of Hart-Scott-Rodino   GlobeNewswire Inc
Sep 8, 2020
02:17AM EDT  Plasma-Centric Drugmaker Grifols To Buy Geriatric Pharma Startup Alkahest   Benzinga
Sep 3, 2020
12:53PM EDT  Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies:   GlobeNewswire Inc
Sep 1, 2020
07:17PM EDT  Lifshitz Law Firm, P.C. Announces Investigation of Cancer   GlobeNewswire Inc
Aug 26, 2020
06:39PM EDT  Jernigan Capital, Inc., Momenta Pharmaceuticals, Inc., NTN Buzztime, Inc., Principia Biopharma Inc., Spring Bank Pharmaceuticals, Inc., Varian Medical Systems, Inc., and Yintech Investment Holdings Limited   PR Newswire
Aug 25, 2020
09:35AM EDT  Benzinga's Top Upgrades, Downgrades For August 25, 2020   Benzinga
06:12AM EDT  HC Wainwright & Co. Downgrades Momenta Pharmaceuticals to Neutral, Announces $52.5 Price Target   Benzinga
Aug 22, 2020
05:00AM EDT  Mergers; Shareholders are Encouraged to Contact the Firm - MVC, PRNB, YIN, MNTA   PR Newswire
Aug 20, 2020
11:10PM EDT  Johnson & Johnson Borrows $7.5B To Fund Its Purchase Of Momenta   Benzinga
01:45PM EDT  Moore Kuehn Encourages NTN, PRNB, MNTA, and PFNX Investors to Contact Law Firm   PR Newswire
11:42AM EDT  MOMENTA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Momenta Pharmaceuticals, Inc. - MNTA   Business Wire
09:51AM EDT  Benzinga's Top Upgrades, Downgrades For August 20, 2020   Benzinga
08:52AM EDT  10 Biggest Price Target Changes For Thursday   Benzinga
07:51AM EDT  Cantor Fitzgerald Maintains Neutral on Momenta Pharmaceuticals, Raises Price Target to $52.5   Benzinga
06:22AM EDT  Truist Securities Downgrades Momenta Pharmaceuticals to Hold   Benzinga
06:20AM EDT  Stifel Downgrades Momenta Pharmaceuticals to Hold, Raises Price Target to $52.5   Benzinga
Aug 19, 2020
06:35PM EDT  SHAREHOLDER ALERT: WeissLaw LLP Investigates Momenta Pharmaceuticals, Inc.   PR Newswire
03:55PM EDT  Momenta Pharmaceuticals Option Alert: Dec 18 $55 Calls at the Ask: 1190 @ $0.25 vs 58 OI; Ref=$52.12   Benzinga
02:32PM EDT  Mid-Afternoon Market Update: Momenta Pharmaceuticals Jumps Following Acquisition News; Galapagos Shares Slide   Benzinga
02:20PM EDT  INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of   PR Newswire
12:59PM EDT  MOMENTA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long,   GlobeNewswire Inc
12:03PM EDT  Mid-Day Market Update: Gold Falls Over 2%; Hudson Shares Spike Higher   Benzinga
11:33AM EDT  ROCE Insights For Momenta Pharmaceuticals   Benzinga
10:16AM EDT  Wells Fargo Downgrades Momenta Pharmaceuticals to Equal-Weight, Raises Price Target to $52.5   Benzinga
10:14AM EDT  Mid-Morning Market Update: Markets Mostly Higher; Target Tops Q2 Views   Benzinga
08:16AM EDT  Truist Securities Analyst Robyn Karnauskas On J&J: Co May Have Underpaid For Momenta By Paying $52.50/Share   Benzinga
07:39AM EDT  (MNTA) Alert: Johnson Fistel Investigates Proposed Sale of Momenta   PR Newswire
07:21AM EDT  Johnson & Johnson to Acquire Momenta Pharmaceuticals For $52.50/Share, Representing a Total Equity Value of $6.5B   Benzinga
06:47AM EDT  Johnson & Johnson To Acquire Momenta Pharmaceuticals -   RTTNews
06:36AM EDT  Johnson & Johnson to Acquire Momenta Pharmaceuticals For $6.5B In Cash   Benzinga
06:35AM EDT  -- Johnson & Johnson to acquireMomentafor $52.50 per share in cash, representing a total equity value of $6.5 billion and a 70% premium to Momentas closing price on August 18, 2020   GlobeNewswire Inc
Aug 10, 2020
07:49AM EDT  Momenta Pharmaceuticals Q2 EPS $(0.48) Misses $(0.39) Estimate, Sales $6.61M Beat $5.56M Estimate   Benzinga
07:28AM EDT  Recap: Momenta Pharmaceuticals Q2 Earnings   Benzinga
07:00AM EDT  -- Interim Phase 2 Vivacity-MG results met primary endpoints, demonstrating nipocalimab was well-tolerated and achieved rapid and durable responses with significant correlation (p<0.0001) between IgG reduction and MG-ADL clinical benefit in MG; full data expected by Q4 2020   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Aug 3, 2020
07:30AM EDT  Momenta Pharmaceuticals,Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the second quarter ended June 30, 2020 before the U.S. financial markets open on Monday, August 10, 2020.   GlobeNewswire Inc
Jul 29, 2020
06:07AM EDT  HC Wainwright & Co. Maintains Buy on Momenta Pharmaceuticals, Raises Price Target to $50   Benzinga
Jul 28, 2020
10:02AM EDT  Momenta Pharmaceuticals shares are trading higher after the company announced it has received FDA rare pediatric disease designation for Nipocalimab in HDFN.   Benzinga
07:19AM EDT  Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease Designation For Nipocalimab In HDFN   Benzinga
07:15AM EDT  Momenta Pharmaceuticals Announces FDA Rare Pediatric Disease   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC